Medical/Pharmaceuticals
SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson's using the SYMBYX Neuro - a new light therapy wellness helmet
SYDNEY, March 17, 2023 /PRNewswire/ -- SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects ...
2023-03-17 18:30
2860
GCCL Develops PBMC Resource Management System
To enhance accuracy and credibility of sample management and provide real-time information for customers YONGIN, South Korea, March 16, 2023 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a company specializes in clinical trial sample analysis, announced onMar. 17 that it has built a resour...
2023-03-17 09:26
2329
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients
SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...
2023-03-16 21:00
2534
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 goze...
2023-03-16 20:28
2595
Akeso Reported 2022 Annual Results
* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales ofRMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales ofRMB...
2023-03-16 08:26
5211
Lunit to Present 5 Abstracts at the 2023 AACR Annual Meeting
* Five posters from Lunit and collaborators demonstrate important progress in the development of novel diagnostics for important cancer therapies, including immunotherapy SEOUL, South Korea, March 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer sol...
2023-03-15 21:14
2992
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
* The abstract of BBT-207 preclinical studies is now available on the AACR
website
2023-03-15 21:00
3182
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...
2023-03-15 19:00
2841
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...
2023-03-15 10:45
3928
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical s...
2023-03-15 07:59
3721
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011
SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011. The study (CTR20230046) is a phase 1, single cente...
2023-03-14 23:42
3192
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreeme...
2023-03-14 20:00
3600
Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer
HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world's first approved and marketed dual-immune checkpoint bi-specific antib...
2023-03-14 17:01
2456
DeepCare debuts at IDS Cologne 2023
COLOGNE, Germany, March 14, 2023 /PRNewswire/ -- DeepCare, a leading AI solution provider for dental care, debuts its latest innovative products at the International Dental Show (IDS) inCologne, Germany, from March 14th to 18th, 2023. IDS is the world's largest and most influential dental exhibit...
2023-03-14 16:00
2857
Austco Augments Industry-leading Nurse Call and Healthcare Communications Solutions with 4D Imaging Radar Fall Detection by Vayyar
International partnership will see sensor installations in senior care
facilities in all of Austco's operating regions, includingAustralia, the UK,
Canada, and the US.
DALLAS and TEL AVIV, Israel, March 13, 2023 /PRNewswire/ -- Austco
2023-03-13 22:00
3427
Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors
SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines. The partnership aims to accelerate the development of T-...
2023-03-13 20:00
2978
Zhongchao Inc. Releases Survey Results for Bone Marrow Cancer Patient Services with More than 80% Patients Indicating Full Satisfaction
SHANGHAI, March 13, 2023 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the survey results of bone marrow patient services provided by ...
2023-03-13 20:00
2850
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
TAIPEI, March 10, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S.,Canada, European Union, Great Britain, and Israel for spinal ...
2023-03-10 19:00
2474
Success for Surglasses Technology! First AR Surgery Completed in the United States
TAICHUNG, Taiwan, March 10, 2023 /PRNewswire/ -- Surglasses/Caduceus S from Taiwan Main Orthopaedic Biotechnology Co., Ltd. Achieves Landmark Success with Caduceus S AR Spine Navigation System for First Augmented Reality Surgery in the US using 2D C-Arm Imaging. Surglasses has achieved a signifi...
2023-03-10 16:26
2873
Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing
BOSTON, March 9, 2023 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a$50 million Series B financing round, co-led by INCE Capital and Qiming Venture Partners, w...
2023-03-10 09:00
3016
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24